Porphyria cutanea tarda: Multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency

Digestive Diseases and Sciences

Volumn 47, Issue 2, 2002, Pages 419-426

  Egger, Norman G ^a,b   Goeger, Douglas E ^a   Payne, Deborah A ^b   Miskovsky, Emil P ^b   Weinman, Steven A ^b   Anderson, Karl E ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Hemochromatosis; Hepatitis C; HFE gene; Iron; Porphyria; Uroporphyrinogen decarboxylase

Indexed keywords

ESTROGEN; UROPORPHYRINOGEN DECARBOXYLASE;

ALCOHOL CONSUMPTION; ARTICLE; CLINICAL ARTICLE; ENZYME DEFICIENCY; GENE HFE; GENE MUTATION; GENOTYPE; HEMOCHROMATOSIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PORPHYRIA CUTANEA TARDA; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SMOKING;

ALCOHOL DRINKING; ESTROGENS; FEMALE; HEMOCHROMATOSIS; HEPATITIS C; HIV INFECTIONS; HUMANS; MUTATION; PORPHYRIA CUTANEA TARDA; RISK FACTORS; SMOKING; UROPORPHYRINOGEN DECARBOXYLASE;

EID: 0036164415     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013746828074     Document Type: Article

References (65)

1. Disorders of heme biosynthesis: X-linked sideroblastic anemias and the porphyrias
2. Porphyria cutanea tarda
3. Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda
4. Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: The influence of virus C infection
5. Oxidation of uroporphyrinogens by hydroxyl radicals. Evidence for nonporphyrin products as potential inhibitors of uroporphyrinogen decarboxylase
6. Drug induced abnormalities of liver heme biosynthesis
7. Direct spectrophotometry of diluted erythrocytes and plasma: A rapid diagnostic method in primary and secondary porphyrinemias
8. A plasma porphyrin fluorescence marker for variegate porphyria
9. Accumulation of porphyrins in plasma and tissues of dogs after δ-aminolevulinic acid administration: Implications for photodynamic therapy
10. The occurrence and determination of δ-aminolevulinic acid and porphobilinogen in urine
11. Direct spectrofluorophotometric determination of porphyrin in diluted urine
12. Rapid procedure for fecal porphyrin assay
13. Effects of chloroquine in hematoporphyrin-treated animals
14. An assay of uroporphyrinogen decarboxylase in erythrocytes
15. Porphyria cutanea tarda. Clinical features and laboratory findings in 40 patients
16. Ascorbic acid deficiency in porphyria cutanea tarda
17. Liposoluble vitamins and naturally occurring carotenoids in porphyria cutanea tarda
18. Association between reactive oxygen species and disease activity in chronic hepatitis C
19. The effect of desferrioxamine on iron metabolism and lipid peroxidation in hepatocytes of C57BL/ 10 mice in experimental uroporphyria
20. Oxygen radical generation by microsomes: Role of iron and implications for alcohol metabolism and toxicity
21. Vitamin C reduces the incidence and severity of renal tumors induced by estradiol or diethylstilbestrol
22. Effect of estradiol on the induction of porphyria by hexachlorobenzene in the rat
23. Estrogen and antioxidants in hexachlorobenzene-induced hepatic porphyria in rats
24. Ascorbic acid inhibition of cytochrome P-450-catalyzed uroporphyrin accumulation
25. Ascorbic acid inhibits chemically induced uroporphyria in ascorbate-requiring rats
26. Polycyclic aromatic hydrocarbons cause hepatic porphyria in iron-loaded C57BL/10 mice: Comparison of uroporphyrinogen decarboxylase inhibition with induction of alkoxyphenoxazone dealkylations
27. Role of iron in the hydrogen peroxide-dependent oxidation of hexahydroporphyrins (porphyrinogens): A possible mechanism for the exacerbation by iron of hepatic uroporphyria
28. Effects of iron-EDTA on uroporphyrinogen oxidation by liver microsomes
29. Uroporphyrinogen oxidation catalyzed by reconstituted cytochrome P- 450IA2
30. Uroporphyria produced in mice by iron and 5-aminolaevulinic acid does not occur in Cypla2(-/-) null mutant mice
31. Uroporphyrinogen oxidation catalyzed by human cytochromes P 450
32. Hepatitis-C virus and porphyria cutanea tarda - Evidence of a strong association
33. Hepatitis-C virus antibodies and liver disease in patients with porphyria cutanea tarda
34. Porphyria cutanea tarda and hepatitis C and B viruses infection: A retrospective study
35. Porphyria cutanea tarda and hepatitis C virus: A case-control study and meta-analysis of the literature
36. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America
37. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda
38. Low prevalence of hepatitis C virus infection in porphyria cutanea tarda in Germany
39. Hepatocellular carcinoma in porphyria cutanea tarda: Frequency and factors related to its occurrence
40. Porphyria cutanea tarda associated with the acquired immune deficiency syndrome
41. Porphyria cutanea tarda associated with human immunodeficiency virus infection. A study of four cases and review of the literature
42. Human immunodeficiency virus infection and porphyria cutanea tarda: Coexistence of risk factors or causative association?
43. Porphyria cutanea tarda associated with human immunodeficiency virus infection
44. New developments in hereditary hemochromatosis
45. Molecular medicine and hemochromatosis: At the crossroads
46. Phenotypic expression of HFE mutations: A French study of 1110 unrelated iron-overloaded patients and relatives
47. A simple genetic test identifies 90% of UK patients with haemochromatosis. The UK Haemochromatosis Consortium
48. Hemochromatosis: Genetics helps to define a multifactorial disease
49. HFE S 65C variant is not associated with increased transferrin saturation in voluntary blood donors
50. Two novel missense mutations of the HFE gene (I105T and G93R) and identification of the S 65C mutation in Alabama hemochromatosis probands
51. Commentary on HFE S65C variant is not associated with increased transferrin saturation in voluntary blood donors by Naveen Arya, Subrata Chakrabrati, Robert A. Hegele, Paul C. Adams
52. LightCycler PCR assay for simultaneous detection of the H 63D and S65C mutations in the HFE hemochromatosis gene based on opposite melting temperature shifts
53. HFE mutations analysis in 711 hemochromatosis probands: Evidence for S 65C implication in mild form of hemochromatosis
54. A novel mutation of HFE explains the classical phenotype of genetic hemochromatosis in a C 282Y heterozygote
55. Increased frequency of haemochromatosis Cys 282Tyr mutation in sporadic porphyria cutanea tarda
56. The haemochromatosis C282Y mutation in sporadic and familial porphyria cutanea tarda
57. The frequency of hemochromatosis-associated alleles is increased in British patients with sporadic porphyria cutanea tarda
58. The C282Y mutation in the haemochromatosis gene (HFE) and hepatitis C virus infection are independent cofactors for porphyria cutanea tarda in Australian patients
59. Mutations of the hereditary hemochromatosis candidate gene HLA-H in porphyria cutanea tarda
60. High prevalence of the His 63Asp HFE mutation in Italian patients with porphyria cutanea tarda
61. The most frequent HFE allele linked to porphyria cutanea tarda in Mediterraneans is His63Asp
62. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C
63. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C
64. Analysis of uroporphyrinogen decarboxylase complementary DNAs in sporadic porphyria cutanea tarda
65. C282Y and H63D mutations in the HFE gene are not associated with porphyria cutanea tarda in Bulgaria